Organization

Yumanity Therapeutics, Inc.

About

Yumanity is a biopharmaceutical company specifically focused on discovering and developing innovative novel therapies to treat devastating neurodegenerative diseases with a critical unmet need. Target conditions include large or orphan disease markets, such as Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, or MSA, amyotrophic lateral sclerosis, or ALS, and frontotemporal lobar dementia, or FTLD.

Overview

Founded 2014
Type Public
Location Boston, Massachusetts, USA

Stock

YMTX $1.62 0.00% $0.00

Latest News

Yumanity Therapeutics Announces Filing of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta Aug 29, 2022 GlobeNewswire Inc. BOSTON, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. (“Yumanity”) (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative,...
Yumanity Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Developments Aug 04, 2022 GlobeNewswire Inc. BOSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. (“Yumanity” or the “Company”) (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and...
Best Penny Stocks to Buy That Exploded Today? 3 to Watch Jun 06, 2022 PennyStocks Check these penny stocks out for your watchlist right now The post Best Penny Stocks to Buy That Exploded Today? 3 to Watch appeared first...
Benzinga's Premarket Brief On Trending Tickers: Amazon, Alibaba, DiDi, Solaredge, And More Jun 06, 2022 Benzinga Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news items possibly...
Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions Jun 06, 2022 GlobeNewswire Inc. Yumanity Therapeutics, Inc. to sell its clinical-stage product candidate YTX-7739 as well as its unpartnered discovery-stage neuroscience product candidates and targets to Janssen Pharmaceutica NV...